Skip to content
10-Q

Quarterly Report

KalVista Pharmaceuticals, Inc. KALV

0001193125-26-223976

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 53.24M sh
Shares Diluted Q1 2026 · Mar 31, 2026 54.58M sh
Shares Diluted Q1 2026 · Mar 31, 2025 53.07M sh
Capex Q1 2026 · Mar 31, 2026 $121K
Capex Q1 2026 · Mar 31, 2025 $288K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$14.46M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$47.57M
Long Term Debt Q1 2026 · Mar 31, 2026 $172.21M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $213.77M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $229.34M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$19.65M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$2.71M
Stockholders Equity Q1 2026 · Mar 31, 2025 $116.76M
Stockholders Equity Q1 2026 · Dec 31, 2024 $164.36M
Current Liabilities Q1 2026 · Mar 31, 2026 $60.82M
Current Liabilities Q1 2026 · Dec 31, 2025 $57.36M
Total Liabilities Q1 2026 · Mar 31, 2026 $348.57M
Total Liabilities Q1 2026 · Dec 31, 2025 $338.09M
Current Assets Q1 2026 · Mar 31, 2026 $314.21M
Current Assets Q1 2026 · Dec 31, 2025 $320.15M
Total Assets Q1 2026 · Mar 31, 2026 $328.92M
Total Assets Q1 2026 · Dec 31, 2025 $335.38M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.43
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.98
Eps Basic Q1 2026 · Mar 31, 2026 −$0.43
Eps Basic Q1 2026 · Mar 31, 2025 −$0.98
Sga Expense Q1 2026 · Mar 31, 2026 $48.8M
Sga Expense Q1 2026 · Mar 31, 2025 $35.54M
Rd Expense Q1 2026 · Mar 31, 2026 $12.42M
Rd Expense Q1 2026 · Mar 31, 2025 $14.17M
Net Income Q1 2026 · Mar 31, 2026 −$23.49M
Net Income Q1 2026 · Mar 31, 2025 −$51.84M
Operating Income Q1 2026 · Mar 31, 2026 −$23.44M
Operating Income Q1 2026 · Mar 31, 2025 −$49.71M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $3.09M
Revenue Q1 2026 · Mar 31, 2026 $40.86M